4D Molecular Therapeutics shares are trading lower by 12.7% Wednesday afternoon. The company announced pricing of an upsized underwritten public offering.
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 974,797 shares changed hands during mid-day trading, a decline of 25% from the previous session’s volume of 1,293,429 shares.The stock last traded at $30.87 and had previously closed at $33.21. Wall Street Analyst Weigh In Several […]
Monday, 4D Molecular Therapeutics FDMT released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular…
51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable.